Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Gluck, M. R. Articles by Haroutunian, V. Search for Related Content PubMed Citation Articles by Gluck, M. R. Articles by Haroutunian, V. Neurophysiology Geriatric Psychiatry Schizophrenia Spectrum Disorders

Implications for Altered Glutamate and GABA Metabolism in the Dorsolateral Prefrontal Cortex of Aged Schizophrenic Patients

OBJECTIVE: Pharmacological, clinical, and postmortem studies suggest altered -aminobutyric acid (GABA)-ergic and glutamatergic function in patients with schizophrenia. The dorsolateral prefrontal cortex is one key locus of abnormality. The precise neurochemical mechanisms underlying neurotransmitter alterations, such as hypoglutamatergia or GABA dysfunction, are not well understood. This study investigated key biochemical elements of GABA and glutamate metabolism in brain specimens from schizophrenic patients. The activities of nine principal GABA and glutamate-associated metabolic enzymes were measured concurrently in the dorsolateral prefrontal cortex of antemortem-assessed and neuropathologically characterized schizophrenic and comparison subjects. METHOD: Postmortem dorsolateral prefrontal cortex specimens from schizophrenia, Alzheimer’s disease, and normal nonpsychiatric comparison subjects were assayed to determine activities of the principal glutamate and GABA-metabolizing enzymes glutamine synthetase, glutamate dehydrogenase, -ketoglutarate dehydrogenase, phosphate-activated glutaminase, alanine aminotransferase, aspartate aminotransferase, glutamic acid decarboxylase, GABA-transaminase, and succinic semialdehyde dehydrogenase. RESULTS: Glutamic acid decarboxylase activities were twofold greater and phosphate-activated glutaminase activities were fourfold greater in the schizophrenic group than in the comparison group. Differences in postmortem interval, tissue pH, inhibition of phosphate-activated glutaminase, and medication effects could not account for the differences. Differences in phosphate-activated glutaminase and glutamic acid decarboxylase activities in equivalent specimens from Alzheimer’s patients were not observed. The activities of the remaining enzymes were unchanged. CONCLUSIONS: Greater phosphate-activated glutaminase and glutamic acid decarboxylase activities, specific to schizophrenia patients, provide additional biochemical evidence that dorsolateral prefrontal cortex glutamate and GABA metabolism is altered in schizophrenic subjects. These greater activities are consistent with models of a dysregulated glutamatergic/GABA-ergic state in schizophrenia.

This article has been cited by other articles:

				J. P. Buschdorf, L. Li Chew, B. Zhang, Q. Cao, F.-Y. Liang, Y.-C. Liou, Y. T. Zhou, and B. C. Low Brain-specific BNIP-2-homology protein Caytaxin relocalises glutaminase to neurite terminals and reduces glutamate levels. J. Cell Sci., August 15, 2006; 119(Pt 16): 3337 - 3350. [Abstract] [Full Text] [PDF]

				P. R. Szeszko, B. A. Ardekani, M. Ashtari, S. Kumra, D. G. Robinson, S. Sevy, H. Gunduz-Bruce, A. K. Malhotra, J. M. Kane, R. M. Bilder, et al. White Matter Abnormalities in First-Episode Schizophrenia or Schizoaffective Disorder: A Diffusion Tensor Imaging Study Am J Psychiatry, March 1, 2005; 162(3): 602 - 605. [Abstract] [Full Text] [PDF]

				M. Sarter, C. L Nelson, and J. P Bruno Cortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia Schizophr Bull, January 1, 2005; 31(1): 117 - 138. [Abstract] [Full Text] [PDF]

				K. L. Davis, D. G. Stewart, J. I. Friedman, M. Buchsbaum, P. D. Harvey, P. R. Hof, J. Buxbaum, and V. Haroutunian White Matter Changes in Schizophrenia: Evidence for Myelin-Related Dysfunction Arch Gen Psychiatry, May 1, 2003; 60(5): 443 - 456. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us